Insights Advancing the Future of Pharmaceuticals

Equinox Group specializes in assessing the commercial potential of drug programs in all stages of R&D, delivering quantitative insights in disease area strategy, market access, patient share forecasting, patient flow, and epidemiology.

Years of Experience
30+
Drug Assessments
1,000+

Decision Support at Every Stage of the Asset Lifecycle

Disease Area Strategy

Find out which indications offer the best commercial opportunities and how to prioritize them

BD & Early R&D

Assess an asset's Clinical Innovation and peak share potential, whether evaluating a BD&L opportunity or developing a TPP

Late-Stage Development

Dive into our patient-share forecasting, patient-flow modeling, and market access tools

Compare All Offerings

The Unmet Need Framework

The framework at the heart of our analysis and how we use it to predict patient share

1 Characterize the Unmet Need

2 Measure the Clinical Innovation

Comparison table showing different metrics for Product X and Product Y, including unmet need score, relative unmet need improvement, competitive intensity rating, diagnosed prevalence, annual cost of regimen, and projected peak patient share.

3 Predict Share

See the framework in detail →

Recent Articles

Our Take Blog
MeziKd Figure.png
Oncology
BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more
Oncology
Read more →
Oncology
Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge.
Chronic Diseases
Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge.
Chronic Diseases
Read more →
Chronic Diseases
unmet-need-drivers-comparison-v2 (1).png
Oncology
Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved
Oncology
Read more →
Oncology
PrimaryPrevBanner.png
Chronic Diseases
Lipfendra Brings PCSK9i Efficacy with Oral Convenience
Chronic Diseases
Read more →
Chronic Diseases
bezuclastinib + sunitinib base case Figure.png
Oncology
Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care
Oncology
Read more →
Oncology
Ind2 - Chemo (TROP-2) vs Datroway Figure.png
Oncology
TROP2 ADCs: A Major Innovation for 1L TNBC
Oncology
Read more →
Oncology

Want to get in touch?

Click here